

# Clinical characteristics and predictive value of lower CD4+T cell level in patients with moderate and severe COVID-19: A multicenter retrospective study

**Xue-song Wen**

Chongqing Medical University First Affiliated Hospital

**Dan Jiang**

Chongqing Medical University First Affiliated Hospital

**Lei Gao**

Chongqing Medical University First Affiliated Hospital

**Jian zhong Zhou**

The First Affiliated Hospital of Chongqing Medical University

**Jun Xiao**

Chongqing University Central Hospital: department of cardiovascular medicine  
Chongqing Emergency Medical Center

**Xiao-cheng Cheng**

Chongqing Medical University First Affiliated Hospital

**Bin He**

Chongqing Medical University First Affiliated Hospital

**Yue Chen**

Chongqing Medical University First Affiliated Hospital

**Peng Lei**

Chongqing Medical University First Affiliated Hospital

**Xiao-wei Tan**

Chongqing Medical University First Affiliated Hospital

**Shu Qin**

Chongqing Medical University First Affiliated Hospital

**Dongying Zhang** (✉ [zhangdongying@cqmu.edu.cn](mailto:zhangdongying@cqmu.edu.cn))

Chongqing Medical University First Affiliated Hospital <https://orcid.org/0000-0002-0507-897X>

---

## Research article

**Keywords:** CD4+T cells, COVID-19, In-hospital death, SARS-CoV-2

**Posted Date:** January 8th, 2021

**DOI:** <https://doi.org/10.21203/rs.3.rs-46009/v4>

**License:**  This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

---

**Version of Record:** A version of this preprint was published on January 12th, 2021. See the published version at <https://doi.org/10.1186/s12879-020-05741-w>.

# Abstract

## Background

In December 2019, coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, Hubei, China. Moreover, it has become a global pandemic. This is of great value in describing the clinical symptoms of COVID-19 patients in detail and looking for markers which are significant to predict the prognosis of COVID-19 patients.

## Methods

In this multicenter, retrospective study, 476 patients with COVID-19 were enrolled from a consecutive series. After screening, a total of 395 patients were included in this study. All-cause death was the primary endpoint. All patients were followed up from admission till discharge or death.

## Results

The main symptoms observed in the study included fever on admission, cough, fatigue, and shortness of breath. The most common comorbidities were hypertension and diabetes mellitus. Patients with lower CD4<sup>+</sup>T cell level were older and more often male compared to those with higher CD4<sup>+</sup>T cell level. Reduced CD8<sup>+</sup>T cell level was an indicator of the severity of COVID-19. Both decreased CD4<sup>+</sup>T [HR:13.659; 95%CI: 3.235-57.671] and CD8<sup>+</sup>T [HR: 10.883; 95%CI: 3.277-36.145] cell levels were associated with in-hospital death in COVID-19 patients, but only the decrease of CD4<sup>+</sup>T cell level was an independent predictor of in-hospital death in COVID-19 patients.

## Conclusions

Reductions in lymphocytes and lymphocyte subsets were common in COVID-19 patients, especially in severe cases of COVID-19. It was the CD8<sup>+</sup>T cell level, not the CD4<sup>+</sup>T cell level, that reflected the severity of the patient's disease. Only reduced CD4<sup>+</sup>T cell level was independently associated with increased in-hospital death in COVID-19 patients.

**Trial registration:** Prognostic Factors of Patients With COVID-19, NCT04292964. Registered 03 March 2020.  
<https://clinicaltrials.gov/ct2/show/NCT04292964>. Retrospectively registered.

## 1. Background

In December 2019, an outbreak of coronavirus disease 2019 (COVID-19), an acute respiratory illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was detected in Chinese mainland. Although the overall case fatality rate for COVID-19 patients is relatively low [1], the number of deaths associated with COVID-19 has already exceeded the sum of SARS and MERS, which has brought extraordinary harm to human beings [2]. Moreover, the fatality rate of patients with severe COVID-19 is higher, and the harm is bound to be more critical [3]. This is of great value in describing the clinical symptoms of COVID-19 patients in detail and finding markers to predict the prognosis of COVID-19 patients.

The decrease of T-lymphocytes in peripheral blood was a normal laboratory characteristic in patients with COVID-19, especially in patients with severe COVID-19 [4, 5]. A later study recruited 21 patients with COVID-19, 11 patients with severe COVID-19 and ten patients with moderate COVID-19. The study showed that the absolute numbers of T-lymphocytes, CD4<sup>+</sup>T cells, and CD8<sup>+</sup>T cells were decreased in almost all COVID-19 patients, with significantly lower numbers in patients with severe COVID-19 (294.0, 177.5, and  $89.0 \times 10^6/L$ ) than in patients with moderate COVID-19 (640.5, 381.5, and  $254.0 \times 10^6/L$ ). Meanwhile, the number of B-lymphocytes did not decrease but rather tended to increase in most patients. This phenomenon suggested that SARS-CoV-2 infection may mainly affect T-lymphocytes, especially CD4<sup>+</sup>T cells and CD8<sup>+</sup>T cells [5]. T-lymphocytes play a crucial role in antiviral immunity. The CD4<sup>+</sup>T lymphocyte subsets secreted a high level of effector cytokines, particularly interferon- $\gamma$  (IFN- $\gamma$ ), which were essential for virus clearance [6, 7]. A previous study also showed that a dramatic decrease in total lymphocytes indicated that the coronavirus consumed immune cells and destructed cellular immune function [8]. However, there is insufficient evidence as to whether CD4<sup>+</sup>T cells can predict the prognosis in patients with COVID-19.

## 2. Methods

### 2.1 Subjects

Medical records from 476 patients with confirmed COVID-19 were collected in Hubei General Hospital and Chongqing Three Gorges Central Hospital. Missing CD4<sup>+</sup>T cell level or CD8<sup>+</sup>T cell level data (n=58), malignant tumor (n=8), younger than 18 years (n=11), eGFR $\leq 30\text{ml}/\text{min}$  (n=3), and pregnant (n=1) were excluded, patients with immune system diseases or HIV, which may affect lymphocyte subsets, were also excluded. Finally, 395 patients with COVID-19 were analyzed in this study (Figure 1). The positive infected patients were confirmed by testing new coronavirus nucleic acid by real-time fluorescent Polymerase Chain Reaction (RT-PCR). Patients with severe COVID-19 were defined according to the New Coronavirus Pneumonia Prevention and Control Program issued by the National Health Commission of the People's Republic of China (5th edition). Patients with respiratory distress (respiratory rates  $\geq 30$  breaths/minute or resting oxygen saturation  $\leq 93\%$  or partial pressure of arterial oxygen (PaO<sub>2</sub>)/ inspired oxygen fraction (FiO<sub>2</sub>)  $\leq 300\text{mmHg}$  or respiratory failure requiring mechanical ventilation) were defined as severe COVID-19, and the remaining patients were defined as moderate COVID-19 patients. According to the levels of CD4<sup>+</sup>T cell, CD8<sup>+</sup>T cell, and lymphocyte (the lower limit of the laboratory reference value), the patients with COVID-19 were divided into lower group and higher group. The study was a multicenter, retrospective, observational registry with clinicaltrials.gov identifier NCT04292964. All study procedures were approved by the local ethics committee (approval number 20200701). All data were collected by experienced researchers using blinded methods.

### 2.2 Baseline data and follow-up

Demographic and clinical characteristics were collected from the electronic medical record system. Data collection for laboratory results was defined by the results of the first test after hospital admission. The absolute number of lymphocytes was measured by an automatic blood cell analyzer. Peripheral blood lymphocyte subsets were detected by flow cytometry (BD FACSCanto II flow cytometer, BD Biosciences, USA). Data from both clinical centers were standardized, and the standardized tables were used to collect clinical

data from COVID-19 patients. All COVID-19 patients in the study were followed-up from admission to death or discharge from the hospital. The outcome was defined as in-hospital death.

### 2.3 Statistical analysis

Continuous data were expressed as mean  $\pm$  standard deviation (SD) or median (interquartile range) according to the distribution. Categorical variables were expressed as frequency rates with percentages. Continuous variables were compared using the independent samples T-test (normal distribution) and the Mann-Whitney U-test (nonnormal distribution). Categorical data were tested using the Chi-square test and Fisher's exact Chi-square test. Univariate analyses and multivariate analyses were performed using Cox proportional-hazards models to determine the relationship between CD4 $^{+}$ T cell level and in-hospital death. Kaplan-Meier survival analysis with a log-rank test was performed to estimate the cumulative survival rate of groups with higher or lower CD4 $^{+}$ T cell level. Statistical analyses were performed by the IBM SPSS Statistics 26.0 software (SPSS, Chicago, IL, USA). P (two-tailed) value less than 0.05 was considered statistical significance.

## 3. Results

### 3.1 Baseline characteristics

Baseline characteristics are shown in Table 1. The mean age of all COVID-19 patients was 53 years, and 204 patients (51.6%) were male. In these patients, fever on admission (263, 66.6%) was the most common symptom. Cough, shortness of breath, fatigue, and sputum production were present in 257 patients (65.1%), 118 patients (29.9%), 107 patients (27.2%), and 102 patients (25.9%), respectively. In our study, Headache (36, 9.1%), nausea or vomiting (36, 9.1%), myalgia or arthralgia (34, 8.6%), sore throat (22, 5.6%), and chill (7, 6.7%) were rare. The most common comorbidities were hypertension (102, 25.8%) and diabetes mellitus (47, 11.3%). The rates of coronary heart disease, hepatitis B infection, and chronic obstructive pulmonary disease were 6.4% (25/392), 2.3% (9/392), and 1.5% (6/392), respectively.

The 395 COVID-19 patients were divided into two groups according to the lower limit of laboratory CD4 $^{+}$ T cell level reference value: the lower CD4 $^{+}$ T cell level group and the higher CD4 $^{+}$ T cell level group. Patients in the lower group were older ( $55.0 \pm 16.5$  vs  $51.3 \pm 14.8$ ,  $P=0.033$ ), more male (115/195 [59.0%] vs 89/111 [44.5%],  $P=0.004$ ), and more likely to have shortness of breath (75/195 [38.5%] vs 43/200 [21.5%],  $P<0.001$ ) and fever on admission (141/195 [72.3%] vs 122/200 [61.0%],  $P=0.017$ ). There was no apparent difference between the two groups in the prevalence of comorbidities such as hypertension, diabetes mellitus, coronary heart disease, hepatitis B infection, and chronic obstructive pulmonary disease. The same trend were observed in the analysis of patients with moderate and severe COVID-19 alone (Supplementary table1, Supplementary table 2).

### 3.2 Laboratory and Radiographic Findings

In these 395 COVID-19 patients, Hs-CRP (5.0 [2.2-22.9] mg/L) and PCT (0.05 [0.03-0.08] ng/ml) levels were elevated, while lymphocytes, CD4 $^{+}$ T and CD8 $^{+}$ T cell levels were all within the standard ranges (Table1). In patients with moderate COVID-19, only Hs-CRP level was elevated. (Supplementary table1). In patients with severe COVID-19, the levels of Hs-CRP, PCT, and D-dimer were elevated, whereas the levels of lymphocytes, CD4 $^{+}$ T cell, and CD8 $^{+}$ T cell were decreased (Supplementary table2). According to lung CT (computed

tomography, CT) findings, the proportions of ground-glass opacity and patchy local shadowing in all COVID-19 patients were 48.7% (170/349) and 38.7% (135/349), respectively.

In terms of laboratory findings, compared with patients in the group with higher CD4<sup>+</sup>T cell level, patients in the group with lower CD4<sup>+</sup>T cell level had lower lymphocytes levels (0.8 [0.6-1.0] vs. 1.5 [1.2-1.8],  $P<0.001$ , cells $\times 10^9/L$ ), CD8<sup>+</sup>T cell level (168.0 [107.0-250.0] vs. 322.0 [244.3-443.5],  $P<0.001$ , cells/ $\mu l$ ) and CD4/CD8 ratio (1.4 [1.1-1.9] vs. 1.8 [1.4-2.3],  $P<0.001$ ), but higher Hs-CRP level (8.2 [5.0-48.5] vs. 4.9 [1.1-7.0],  $P<0.001$ , mg/L) and PCT level (0.06 [0.04-0.11] vs. 0.04 [0.02-0.06],  $P<0.001$ , ng/ml) (Table1). Analysis of patients with moderate and severe COVID-19 alone, there was no significant change in the proportion of decreased CD4<sup>+</sup>T cell level. However, the proportion of decreased CD8<sup>+</sup>T cell level was significantly higher in patients with severe COVID-19 than in patients with moderate COVID-19 (51.5% [102/198] vs. 36.0% [71/197]) (Figure 2A). It was also found that CD8<sup>+</sup>T cell level was more commonly reduced in patients with severe COVID-19 than in patients with moderate COVID-19 (Figure 2B).

In terms of computed tomography findings, the moderate COVID-19 patients in the lower CD4<sup>+</sup>T cell level group more often represented as patchy local shadowing (45 [47.4%] vs. 33 [32.4%],  $P=0.031$ ) compared with the moderate COVID-19 patients in the higher CD4<sup>+</sup>T cell level group. Ground-glass opacity and local patchy shadowing did not differ between the two groups in the whole patient population (Table1).

### 3.3 Treatment and Clinical outcome

In all cases, the use of oxygen inhalation and mechanical ventilation were 84.3% (328/389) and 7.7% (30/388), respectively. The most common treatment was antiviral therapy (388/395, 98.2%), followed by antibiotic therapy (179/395, 45.3%), glucocorticoids therapy (94/395, 23.8%), intravenous immunoglobulin therapy (71/395, 18.2%), and only four patients (4/395, 1.0%) were treated with antifungal drugs. During the follow-up period, 27 patients died (27/395, 6.8%) and the rest were discharged (368/395, 93.2%).

Patients in the lower group required more oxygen inhalation (90.2% [174/193] vs. 78.6% [154/196],  $P=0.002$ ), mechanical ventilation (13.5% [26/193] vs. 2.1% [4/195],  $P<0.001$ ), antibiotic therapy (57.4% [112/195] vs. 33.5% [67/200],  $P<0.001$ ), and glucocorticoid therapy (32.8% [64/195] vs. 15.0% [30/200],  $P<0.001$ ). Other treatments were similar in both groups, such as antiviral therapy, intravenous immunoglobulin therapy, and antifungal therapy. The case in-hospital death rate was significantly higher in patients with lower CD4<sup>+</sup>T cell level than in those with higher CD4<sup>+</sup>T cell level (12.8% [25/195] vs. 1.0% [2/200],  $P<0.001$ ). Details of the treatment of patients with moderate and severe COVID-19 were shown in Supplementary Table1 and Supplementary Table2.

### 3.4 Survival curves of in-hospital death

Kaplan-Meier survival curves for COVID-19 patients grouped by CD4<sup>+</sup>T cell level are shown in Figure3. During follow-up, the in-hospital death rate was higher in the group with lower CD4<sup>+</sup>T cell level than in the group with higher CD4<sup>+</sup>T cell level ( $\log rank<0.001$ ). The same trend was also found in patients with severe COVID-19 ( $\log rank<0.001$ ). Kaplan-Meier survival analysis was not performed for patients with moderate COVID-19 as there were no moderate COVID-19 patients who died during follow-up.

### **3.5 Results of Cox proportional hazards analyses of in-hospital death**

Cox regression analysis was performed to test the relationship between the variables and in-hospital death in patients with COVID-19 (Supplementary Table3). Univariate analysis revealed a 13.659-fold increased risk of in-hospital death in patients with lower CD4<sup>+</sup>T cell level compared to those with higher CD4<sup>+</sup>T cell level (hazard ratio (HR):13.659; 95% confidence intervals (CI):3.235-57.671). Also, age, history of hypertension and COPD, white blood cell and lymphocyte levels, and lower CD8<sup>+</sup>T cell level (HR: 10.883; 95%CI: 3.277-36.145) were associated with an increased risk of in-hospital death in patients with COVID-19 (Supplementary table3).

Multivariate Cox proportional hazards regression survival analysis was performed to identify the independent factors associated with prognosis (Table2). After adjusting for age, sex, and temperature (Mode 1), the HR for in-hospital death in the group with lower CD4<sup>+</sup>T cell level was 14.182 (95%CI: 1.884-106.786,  $P=0.010$ ). After adjusting for history of hypertension and diabetes, shortness of breath (Mode 2), the HR for in-hospital death in the group with lower CD4<sup>+</sup>T cell level was 13.631 (95%CI: 3.190-58.243,  $P<0.001$ ). After adjusting for white blood cells, platelets, and creatinine (Mode 3), the HR for in-hospital death in the group with lower CD4<sup>+</sup>T cell level was 8.170 (95%CI: 1.877-35.566,  $P=0.005$ ). After adjusting for Hs-CRP, PCT, and D-dimer (Mode4), the HR for in-hospital death in the group with lower CD4<sup>+</sup>T cell level was 10.644 (95%CI: 2.439-46.458,  $P=0.002$ ). After adjusting for CD8<sup>+</sup>T cells and lymphocytes (Mode 5), the HR for in-hospital death in the group with lower CD4<sup>+</sup>T cell level was 13.650 (95%CI: 1.976-94.279,  $P=0.008$ ); Furthermore, in this model, the HR for in-hospital death in the group with lower CD8<sup>+</sup>T cell level was 2.873 (95%CI: 0.771-10.709,  $P=0.116$ ) after adjusting for other factors, we thus concluded that reduced CD4<sup>+</sup>T cell level was a better predictor of in-hospital death. After adjusting for age, history of hypertension, shortness of breath, white blood cells, platelets, D-dimer, and CD4/CD8 ratio (Mode 6), the HR for in-hospital death in the group with lower CD4<sup>+</sup>T cell level was 7.656 (95%CI: 1.610-36.396,  $P=0.010$ ). Multivariate analysis showed that a decreased level of CD4<sup>+</sup>T cell was an independent risk factor for in-hospital death. Variables like age, white blood cell, and shortness of breath also showed significance for independently predicting in-hospital death in this study (Figure4). Similarly, Cox proportional hazards analysis was performed in patients with severe COVID-19, and the results also suggested that decreased CD4<sup>+</sup>T cell level was an independent risk factor for in-hospital death (Supplementary table4, Supplementary table5, Supplementary figure1).

## **4. Discussion**

This study revealed the relationship between lymphocyte subpopulations and the severity of COVID-19 or in-hospital mortality in patients with COVID-19. The main symptoms observed in the study included fever on admission, cough, fatigue, and shortness of breath. The most common comorbidities were hypertension and diabetes mellitus. Patients with lower CD4<sup>+</sup>T cell level were older and more often male than those with higher CD4<sup>+</sup>T cell level. Lymphocyte levels and CD8<sup>+</sup>T cell level were significantly lower in the lower CD4<sup>+</sup>T cell level group. Reduced CD8<sup>+</sup>T cell level was an indicator of the severity of COVID-19. Reduced CD4<sup>+</sup>T and CD8<sup>+</sup>T cell levels were both associated with in-hospital death, but only decreased CD4<sup>+</sup>T cell level was an independent predictor for in-hospital death in COVID-19 patients.

We found the reduction of CD8<sup>+</sup>T cell level was associated with the severity of COVID-19. Previous studies suggested that CD4<sup>+</sup>T and CD8<sup>+</sup>T cell levels were reduced in the vast majority of patients with severe or moderate COVID-19 [5, 9-10]. Reduced levels of CD4<sup>+</sup>T and CD8<sup>+</sup>T cell were not only associated with the severity of COVID-19, but also with poor outcomes [9, 11]. In this study, we found that decreased CD4<sup>+</sup>T and CD8<sup>+</sup>T cell levels were common in patients with COVID-19; there was no significant difference in decreased CD4<sup>+</sup>T cell level between patients with moderate and severe COVID-19, while patients with severe COVID-19 were more likely to have decreased CD8<sup>+</sup>T cell level, suggesting that decreased CD8<sup>+</sup>T cell level may reflect the severity of the disease. This result was similar to a previous report which pointed out that the decrease of CD8<sup>+</sup>T lymphocyte subsets level was associated with the severity of COVID-19 [12]. The reason may be that CD8<sup>+</sup>T cytotoxic cells can promote virus clearance by producing many bioactive molecules such as perforin, granzyme and interferon, and therefore the decreased CD8<sup>+</sup>T cell level could reflect the severity of COVID-19 [13].

We found the decrease of CD4<sup>+</sup>T cell level, not CD8<sup>+</sup>T cell level, was an independent risk for in-hospital death in COVID-19 patients. We conducted the univariate analysis, the same as previous reports [9, 11]. The results confirmed that decreased CD4<sup>+</sup>T cell level and CD8<sup>+</sup>T cell level were associated with poor prognosis in COVID-19 patients. We also performed Cox proportional hazard regression, which showed that only decreased CD4<sup>+</sup>T cell level was an independent risk for in-hospital death in COVID-19 patients after adjusting for other confounding factors. Lymphocyte subsets play an important role in maintaining immune system function. CD8<sup>+</sup>T cells are essential for the direct attack and killing of virally infected cells, CD4<sup>+</sup>T cells can influence the differentiation and maturation of other cells by producing cytokines and chemokines, and the secretion of interferon- $\gamma$  is a T-cytokine with both antiviral and immune activity [14, 15]. Patients infected with SARS-CoV-2 exhibit Th1 cells response and use cellular immunity to control the infection [16]. Viral infection causes comprehensive changes in cellular immunity, manifested by a decrease in lymphocytes, changes in the distribution of T cell subsets and an increase in cytokine concentrations [17]. But the mechanisms of SARS-CoV-2 infection leading to the decrease of lymphocytes and lymphocyte subsets remain unclear. Elevated concentrations of IL-10, IL-6, and TNF- $\alpha$  have been reported to be negatively correlated with total T-cell levels, CD4<sup>+</sup>T cell level, and CD8<sup>+</sup>T cell level, respectively. Compared with patients in the illness period, IL-10, IL-6, and TNF- $\alpha$  levels decreased significantly in patients in the decline stage, while total T-cell levels, CD4<sup>+</sup>T cell level, and CD8<sup>+</sup>T cell level were recovered [18, 19]. This phenomenon suggested the decrease of T-cells in COVID-19 patients may be due to the negative effects of high serum concentrations of TNF- $\alpha$ , IL-6, IL-10 on the survival or proliferation of T-cells [18]. Meanwhile, angiotensin-converting enzyme 2 (ACE2) had been reported to be expressed in white blood cells, and lymphopenia may be due to the direct lethal effect of SARS-CoV-2 on lymphocytes by binding to the ACE2 receptors [20, 21].

Increased age and white blood cell count were associated with in-hospital death in our study, which were similar to several reports [22, 23]. The total case fatality rate of COVID-19 patients increased with age, which may be due to their frequently associated other chronic diseases, as well as lymphocytes and lymphocyte subsets decreased with age [22]. White blood cell count and neutrophil count of dead COVID-19 patients were higher than those of surviving COVID-19 patients, and leukocyte counts were negatively associated with the risk of death, which may be related to cytokine storm caused by the invasion of SARS-CoV-2 [23]. Patients with

malignancy or immune system diseases may be at increased risk of severe COVID-19 and death [24]. To avoid these confounders, all patients with malignancy or immune system diseases were excluded from the study.

This study was limited by sample size and lacked a dynamic detection of CD4<sup>+</sup>T and CD8<sup>+</sup>T cell levels. Firstly, only 395 patients with COVID-19 were analyzed in our study, a relatively small sample size that may affect the statistical power. Secondly, the lack of dynamic measurement for CD4<sup>+</sup>T and CD8<sup>+</sup>T cell levels in the patients included in this study made the evaluation of the relationship between CD4<sup>+</sup>T cell level and disease changes in COVID-19 patients incomplete.

## 5. Conclusions

In summary, the main findings of this study were that it was the CD8<sup>+</sup>T cell level, not the CD4<sup>+</sup>T cell level, reflected the severity of the disease, and that decreased CD4<sup>+</sup>T cell level were important in predicting the prognosis of COVID-19 patients. Both decreased CD4<sup>+</sup>T and CD8<sup>+</sup>T cell levels were associated with in-hospital death in COVID-19 patients, but only the reduction of CD4<sup>+</sup>T cell level was independently associated with increased in-hospital death in COVID-19 patients. Thus, in this acute-care setting, CD4<sup>+</sup>T cell level may provide early prognostic information in patients with COVID-19.

## List Of Abbreviations

SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2; COVID-19, Coronavirus Disease 2019; RT-PCR, Reverse transcription polymerase chain reaction; SARS, Severe acute respiratory syndrome; MERS, Middle East respiratory syndrome; ACE2, Angiotensin-converting enzyme 2; CT, Computed tomography; COPD, chronic obstructive pulmonary disease; CHD, coronary heart disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; WBC, white blood cell count; Hb, Hemoglobin; PLT, platelet; LYM, lymphocyte; ALT, alanine aminotransferase; Cr, creatinine; Hs-CRP, hypersensitive C-reactive protein; PCT, procalcitonin.

## Declarations

**Ethics approval and consent to participate:** All study procedures were approved by the ethics committee of the First Affiliated Hospital of Chongqing Medical University (approval NO. 20200701). The ethics committee listed above approved verbal consent because of the urgency of the situation at the time of the COVID-19 pandemic and the fact that the data used in this study were collected during routine medical procedures, which did not pose any additional risk to the patients. All participants provided fully informed verbal consent before being enrolled in this study. The data used in this study were anonymized prior to use.

**Consent for publication:** Not Applicable.

**Availability of data and materials:** The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Competing interests:** All authors declare no conflict of interest.

**Funding:** This work was supported by the National Natural Science Foundation of China, 81970203; National Natural Science Foundation of China, 81570212; National Natural Science Foundation of China, 31800976. The funding body was not involved in the design of the study, the collection, analysis, and interpretation of data, nor in the writing of the manuscript.

**Authors' Contributions:** W.X. participated in study design, data analysis, and manuscript writing. J.D. and G.L. were involved in manuscript writing. Z.J. and X.J. were involved in data analysis. C.X., H.B., C.Y., L.P., and T.X. were involved in data collection and data analysis. Q.S. and Z.D. were responsible for the study concept, design, and final approval of the manuscript. W.X. is the first author. All authors have read and approved the final manuscript.

**Acknowledgments:** We thank all participants involved in this study. We thank all medical staff who participated in the fight against SARS-CoV-2.

## References

- [1] Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med.* 2020; 382: 1708-1720. doi: 10.1056/NEJMoa2002032.
- [2] Lei Gao, Dan Jiang, Xue-Song Wen, Xiao-Cheng Cheng, Min Sun, Bin He, et al. Prognostic value of NT-proBNP in patients with severe COVID-19. *Respir Res.* 2020; 21: 83. doi: 10.1186/s12931-020-01352-w.
- [3] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* 2020; 395: 497-506. doi: 10.1016/S0140-6736(20)30183-5.
- [4] Wei-Jie Guan, Zheng-Yi Ni, Yu Hu, Wen-Hua Liang, Chun-Quan Ou, Jian-xing He, et al. Clinical characteristics of 2019 novel coronavirus infection in China. *medRxiv* 2020.02.06.20020974; doi: <https://doi.org/10.1101/2020.02.06.20020974>.
- [5] Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. *J Clin Invest.* 2020; 130:2620-2629. doi: 10.1172/JCI137244.
- [6] Sarawar, S. R., M. Sangster, R. L. Coffman, P. C. Doherty. Administration of anti-IFN-gamma antibody to beta 2-microglobulin-deficient mice delays influenza virus clearance but does not switch the response to a T helper cell 2 phenotype. *J Immunol.* 1994; 153: 1246-53.
- [7] Topham, D. J., R. A. Tripp, S. R. Sarawar, M. Y. Sangster, P. C. Doherty. Immune CD4<sup>+</sup> T cells promote the clearance of influenza virus from major histocompatibility complex class II/2/respiratory epithelium. *J Virol.* 1996; 70: 1288-1291. doi: 10.1128/JVI.70.2.1288-1291.1996.
- [8] Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet.* 2020; 395: 507-513. doi: 10.1016/S0140-6736(20)30211-7.
- [9] Haipeng Zhang, Ti Wu. CD4<sup>+</sup>T, CD8<sup>+</sup>T counts and severe COVID-19: A meta-analysis. *J Infect.* 2020; 81: e82-e84. doi: 10.1016/j.jinf.2020.06.036.

- [10] Suxin Wan, Qingjie Yi, Shbing Fan, Jinglong Lv, Xianxiang Zhang, Lian Guo, et al. Characteristics of lymphocyte subsets and cytokines in Peripheral Blood of 123 hospitalized patients with 2019 novel Coronavirus pneumonia (NCP). doi: <https://doi.org/10.1101/2020.02.10.20021832>.
- [11] Zeming Liu, Wei Long, Mengqi Tu, Sichao Chen, Yihui Huang, Shipei Wang, et al. Lymphocyte subset (CD4<sup>+</sup>, CD8<sup>+</sup>) counts reflect the severity of infection and predict the clinical outcomes in patients with COVID-19. *J Infect.* 2020; 81: 318-356. doi: 10.1016/j.jinf.2020.03.054.
- [12] J M Urra, C M Cabrera, L Porras, I Ródenas. Selective CD8 cell reduction by SARS-CoV-2 is associated with a worse prognosis and systemic inflammation in COVID-19 patients. *Clin Immunol.* 2020; 217: 108486. doi: 10.1016/j.clim.2020.108486.
- [13] Milos Jesenak, Miroslava Brndiarova, Ingrid Urbancikova, Zuzana Rennerova, Jarmila Vojtkova, Anna Bobcakova, et al. Immune Parameters and COVID-19 Infection – Associations with Clinical Severity and Disease Prognosis. *Front Cell Infect Microbiol.* 2020; 10: 364. doi: 10.3389/fcimb.2020.00364.
- [14] Hong-Yi Zheng, Mi Zhang, Cui-Xian Yang, Nian Zhang, Xi-Cheng Wang, Xin-Ping Yang, et al. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. *Cell Mol Immunol.* 2020; 17: 541-543. doi: 10.1038/s41423-020-0401-3.
- [15] Diane E Griffin. Are T cells helpful for COVID-19: the relationship between response and risk. *J Clin Invest.* 2020; 130: 6222-6224. doi: 10.1172/JCI142081.
- [16] Matthew Zirui Tay, Chek Meng Poh, Laurent Rénia, Paul A MacAry, Lisa F P Ng. The trinity of COVID-19: immunity, inflammation and intervention. *Nat Rev Immunol.* 2020; 20: 363-374. doi: 10.1038/s41577-020-0311-8.
- [17] David Schub, Verena Klemis, Sophie Schneitler, Janine Mihm, Philipp M Lepper, Heinrike Wilkens, et al. High levels of SARS-CoV-2 specific T-cells with restricted functionality in severe course of COVID-19. *JCI Insight.* 2020; 5: e142167. doi: 10.1172/jci.insight.142167.
- [18] Diao B, Wang CH, Tan YJ, Chen XW, Liu Y, Ning LF, et al. Reduction and Functional Exhaustion of T Cells in Patients with Coronavirus Disease 2019 (COVID-19). *MedRxiv*, 2020.02.18.20024364; doi: <https://doi.org/10.1101/2020.02.18.20024364>.
- [19] Menglu Gao, Yili Liu, Mingquan Guo, Qianying Wang, Yan Wang, Jian Fan, et al. Regulatory CD4<sup>+</sup> and CD8<sup>+</sup> T cells are negatively correlated with CD4<sup>+</sup> /CD8<sup>+</sup> T cell ratios in patients acutely infected with SARS-CoV-2. *J Leukoc Biol.* 2020. doi: 10.1002/JLB.5COVA0720-421RR.
- [20] Luka Nicin, Wesley Tyler Abplanalp, Hannah Mellentin, Badder Kattih, Lukas Tombor, David John, et al. Cell type-specific expression of the putative SARS-CoV-2 receptor ACE2 in human hearts. *Eur Heart J.* 2020; 41: 1804-1806. doi: 10.1093/eurheartj/ehaa311.
- [21] Kamal Kant Sahu, Ahmad Daniyal Siddiqui. From Hematologist's desk: The effect of COVID-19 on the blood system. *Am J Hematol.* 2020; 95: E213-E215. doi: 10.1002/ajh.25849.

[22] Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020; 20: 669-677. doi: 10.1016/S1473-3099(20)30243-7.

[23] Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323: 1061-1069. doi: 10.1001/jama.2020.1585.

[24] Monica Fung, Jennifer M Babik. COVID-19 in Immunocompromised Hosts: What We Know So Far. Clin Infect Dis. 2020; ciaa863. doi: 10.1093/cid/ciaa863.

## Tables

**Table 1.** Baseline characteristics of different degrees of CD4<sup>+</sup>T cell level in all COVID-19 patients.

Variables	All(N=395)	CD4+T: lower group (N=195)	CD4+T: higher group (N=200)	P	Missing data
<b>Baseline</b>					
Male/female(n)	204/191	115/80	89/111	0.004	
Age(years)	53.1±15.7	55.0±16.5	51.3±14.8	0.033	
Temperature (°C)	36.8 (36.5-37.3)	36.9 (36.6-37.6)	36.8 (36.5-37.1)	0.036	31 (7.8%)
Heart rate (min)	85.0 (77.0-94.0)	85.0 (78.0-96.0)	84.5 (76.0-92.0)	0.103	4 (1.0%)
SBP (mmHg)	126.0 (116.0-136.0)	126.0 (115.0-136.5)	126.0 (117.0-136.0)	0.577	6 (1.5%)
DBP (mmHg)	78.0 (70.0-85.0)	76.0 (70.0-85.0)	78.0 (71.0-85.0)	0.741	6 (1.5%)
<b>Symptoms and signs---No, %</b>					
Fever on admission	263 (66.6%)	141 (72.3%)	122 (61.0%)	0.017	
Nasal congestion	2 (0.5%)	2 (1.0%)	0 (0%)	0.243	
Headache	36 (9.1%)	20 (10.3%)	16 (8.0%)	0.436	
Cough	257 (65.1%)	138 (70.8%)	119 (59.5%)	0.019	
Sore throat	22 (5.6%)	10 (5.1%)	12 (6.0%)	0.706	
Sputum production	102 (25.9%)	56 (28.9%)	46 (23.0%)	0.184	1 (0.3%)
Fatigue	107 (27.2%)	59 (30.4%)	48 (24.0%)	0.153	1 (0.3%)
Shortness of breath	118 (29.9%)	75 (38.5%)	43 (21.5%)	<0.001	
Nausea or vomiting	36 (9.1%)	23 (11.8%)	13 (6.5%)	0.068	
Myalgia or arthralgia	34 (8.6%)	20 (10.3%)	14 (7.0%)	0.249	
Chill	12 (3.0%)	8 (4.1%)	4 (2.0%)	0.223	
Throat congestion	3 (0.8%)	0 (0%)	3 (1.5%)	0.248	
<b>Coexisting disorders---No, %</b>					
Diabetes	47 (11.9%)	22 (11.3%)	25 (12.5%)	0.709	
Hypertension	102 (25.8%)	48 (24.6%)	54 (27.0%)	0.588	
Coronary heart disease	25 (6.4%)	15 (7.7%)	10 (5.1%)	0.277	3 (0.8%)
Hepatitis B infection	9 (2.3%)	6 (3.1%)	3 (1.5%)	0.334	3 (0.8%)
COPD	6 (1.5%)	5 (2.6%)	1 (0.5%)	0.119	3 (0.8%)
<b>Laboratory findings</b>					
WBC ( $\times 10^9/L$ )	5.3 (4.2-7.0)	5.0 (3.8-7.0)	5.6 (4.5-7.0)	0.008	2 (0.5%)
Hb (g/L)	131.0 (118.5-143.0)	132.0 (117.0-143.0)	129.0 (120.0-142.3)	0.809	2 (0.5%)
PLT ( $\times 10^9/L$ )	189.0 (145.5-252.0)	160.0 (129.0-214.0)	220.5 (170.0-364.0)	<0.001	2 (0.5%)
LYM ( $\times 10^9/L$ )	1.1 (0.8-1.5)	0.8 (0.6-1.0)	1.5 (1.2-1.8)	<0.001	6 (1.5%)
LYM<1.1 $\times 10^9/L$	199 (51.2%)	163 (84.5%)	27 (13.8%)	<0.001	6 (1.5%)
ALT (U/L)	23.0 (15.0-39.0)	24.1 (15.4-38.8)	22.0 (15.0-39.0)	0.388	4 (1.0%)
Cr (umol/L)	64.0 (53.0-78.0)	66.5 (56.0-79.0)	61.0 (50.0-77.0)	0.005	5 (1.3%)
D-dimer (mg/L)	0.43 (0.24-0.99)	0.50 (0.28-1.12)	0.38 (0.22-0.84)	0.023	14 (3.5%)

K (mmol/L)	4.0 (3.7-4.3)	4.0 (3.6-4.3)	4.1 (3.7-4.3)	0.243	6 (1.5%)
Hs-CRP (mg/L)	5.0 (2.2-22.9)	8.2 (5.0-48.5)	4.9 (1.1-7.0)	<0.001	45 (11.4%)
PCT (ng/ml)	0.05 (0.03-0.08)	0.06 (0.04-0.11)	0.04 (0.02-0.06)	<0.001	21 (5.3%)
CD4 <sup>+</sup> T cell level	410.0 (265.0-567.0)	262.0 (188.0-325.0)	564.0 (478.5-716.0)	<0.001	
CD8 <sup>+</sup> T cell level	246.0 (154.0-348.0)	168.0 (107.0-250.0)	322.0 (244.3-443.5)	<0.001	
CD4/CD8 ratio	1.6 (1.2-2.2)	1.4 (1.1-1.9)	1.8 (1.4-2.3)	<0.001	
Abnormalities on chest CT---No, %					
Ground-glass opacity	170 (48.7%)	78 (46.7%)	92 (50.5%)	0.473	46 (11.6%)
Local patchy shadowing	135 (38.7%)	71 (42.5%)	64 (35.2%)	0.159	46 (11.6%)
Treatment--No, %					
Oxygen inhalation	328 (84.3%)	174 (90.2%)	154 (78.6%)	0.002	6 (1.5%)
Glucocorticoids	94 (23.8%)	64 (32.8%)	30 (15.0%)	<0.001	
Antiviral treatment	388 (98.2%)	191 (97.9%)	197 (98.5%)	0.721	
Intravenous immunoglobulin	71 (18.2%)	37 (19.2%)	34 (17.3%)	0.625	5 (1.3%)
Antibiotic treatment	179 (45.3%)	112 (57.4%)	67 (33.5%)	<0.001	
Antifungal treatment	4 (1.0%)	2 (1.0%)	2 (1.0%)	1.000	
Clinical outcome					
Death (No, %)	27 (6.8%)	25 (12.8%)	2 (1.0%)	<0.001	


Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; COPD, Chronic obstructive pulmonary disease; WBC, white blood cell; Hb, Hemoglobin; PLT, platelet; LYM, lymphocyte; ALT, alanine aminotransferase; Cr, creatinine; Hs-CRP, hypersensitive C-reactive protein; PCT, procalcitonin.

**Table2.** Results of multivariate Cox proportional-hazards regression analyzing the effect of baseline variables on in-hospital death in all patients with COVID-19.

Mode	HR (95%CI)	P
Not Adjusted CD4 <sup>+</sup> T level, lower vs. higher	11.659 (3.235-57.64)	0.001
Mode 1		
CD4 <sup>+</sup> T cell level, lower vs. higher	14.182 (1.884-106.08)	
Sex, male vs. female	1.383 (0.561-3.406)	0.481
Age, per 1 year	1.093 (1.052-1.135)	<0.001
Temperature, per 1°C	0.777 (0.445-1.354)	0.372
Mode 2		
CD4 <sup>+</sup> T cell level, lower vs. higher	13.631 (3.190-58.24)	0.001
Hypertension, yes vs. no	5.823 (2.595-13.07)	0.001
Diabetes, yes vs. no	0.824 (0.322-2.113)	0.688
Shortness of breath, yes vs. no	7.848 (2.942-20.934)	0.001
Mode 3		
CD4 <sup>+</sup> T cell level, lower vs. higher	8.170 (1.877-35.56)	0.005
WBC, per 1×10 <sup>9</sup> /L	1.294 (1.193-1.404)	<0.001
PLT, per 1×10 <sup>9</sup> /L	0.992 (0.987-0.997)	0.003
Cr, per 1 umol/L	1.002 (0.995-1.009)	0.576
Mode 4		
CD4 <sup>+</sup> T cell level, lower vs. higher	10.644 (2.439-46.46)	0.002
Hs-CRP, per 1 mg/L	0.989 (0.974-1.005)	0.193
PCT, per 1 ng/ml	1.017 (0.925-1.118)	0.724
D-dimer, per 1 mg/L	1.028 (1.018-1.038)	<0.001
Mode 5		
CD4 <sup>+</sup> T cell level, lower vs. higher	13.650 (1.976-94.20)	0.008
CD8 <sup>+</sup> T cell level, lower vs. higher	3.159 (0.853-11.70)	0.085
CD4/CD8 ratio, per 1 unit	1.422 (1.105-1.830)	0.006
LYM level, lower vs. higher	0.996 (0.306-3.243)	0.994
Mode 6		
CD4 <sup>+</sup> T cell level, lower vs. higher	7.656 (1.610-36.39)	0.010
Age, per 1 year	1.074 (1.034-1.115)	<0.001
Hypertension, yes vs. no	2.031 (0.766-5.386)	0.154
Shortness of breath, yes vs. no	3.435 (1.167-10.11)	0.025
WBC, per 1×10 <sup>9</sup> /L	1.224 (1.097-1.366)	<0.001
PLT, per 1×10 <sup>9</sup> /L	0.996 (0.991-1.001)	0.149
D-dimer, per 1 mg/L	0.997 (0.992-1.002)	0.207
CD4/CD8 ratio, per 1 unit	1.106 (0.793-1.542)	0.552


Abbreviations: WBC, white blood cell; PLT, platelet; Cr, creatinine; Hs-CRP, hypersensitive C-reactive protein; PCT, procalcitonin; LYM, lymphocyte.

## Figures




**Figure 1**

Flow diagram of Patient Recruitment




**Figure 2**

A: The histogram shows the proportion of moderate and severe COVID-19 patients with lymphocyte, CD4<sup>+</sup>T and CD8<sup>+</sup>T cell levels below the lower limit of normal count; B: The histogram shows the number of CD4<sup>+</sup>T cells and CD8<sup>+</sup>T cells in moderate and severe COVID-19 patients.



**Figure 3**

Kaplan-Meier plots shows the survival rate of COVID-19 patients who were stratified into two groups according to CD4+T cell level. (green line, higher CD4+T cell level group; blue line, lower CD4+T cell level group).



**Figure 4**

Forest plots of multivariate Cox proportional-hazards regression analyze the effect of baseline variables on in-hospital death in all patients with COVID-19. Mode1: adjusted sex, age, and temperature; Mode2: adjusted hypertension, diabetes, and shortness of breath; Mode3: adjusted white blood cell, platelet, and Creatinine; Mode4: adjusted hypersensitive C-reactive protein, procalcitonin, and D-dimer; Mode5: adjusted the group with lower CD8+T cell level, CD4/CD8 ratio, and the group with lower lymphocyte level; Mode6: adjusted age, hypertension, shortness of breath, white blood cell, platelet, D-dimer, and CD4/CD8 ratio.

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Supplementaryfigure.docx](#)
- [Supplementarytables.docx](#)